Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells

Docetaxel has been the standard first-line therapy in metastatic castration resistant prostate cancer. The survival benefit is, however, limited by either primary or acquired resistance. In this study, Du145 prostate cancer cells were converted to docetaxel-resistant cells Du145-R and Du145-RB by in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Springerplus
Autors principals: Ma, Yuanjun, Miao, Yali, Peng, Zhuochun, Sandgren, Johanna, De Ståhl, Teresita Díaz, Huss, Mikael, Lennartsson, Lena, Liu, Yanling, Nistér, Monica, Nilsson, Sten, Li, Chunde
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2016
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5078122/
https://ncbi.nlm.nih.gov/pubmed/27822437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40064-016-3543-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars